In recent years, in vitro diagnostic technology has developed rapidly. From gene-level gene sequencing , SNP screening, point mutation gene diagnosis, to various biomarker detection at the protein level, to cell-level circulating tumor cell detection (CTC), and other new technologies and methods. The rise and integration of the in vitro diagnostic (IVD) instruments, reagents development and application and replacement.
On the one hand, technology, on the other hand, the market. What is the domestic in vitro diagnostic market? Let's take a look at the following 10 in vitro diagnostic foreign companies how much money was earned in Q2 this year?
Danaher: Q2 sales of 5.79 billion US dollars, an increase of 17%
Since the acquisition of Beckman Coulter for $6.8 billion, Danaher has jumped to become the world's largest diagnostic company.
Danaher achieved sales of approximately $11 billion in the first half of the year, with Q2 sales of $5.79 billion, an increase of 17% from $4.96 billion in the same period last year, slightly higher than Wall Street’s forecast of $5.76 billion.
Among them, the life sciences sector grew by 5% (strong demand for flow cytometry from the North American and Chinese markets, Beckman's life sciences department grew by 8%); diagnostics sales increased by 2% (Beckman diagnostics are basically flat); testing and Sales in the metrology sector increased from $676 million in the same period last year to $650 million, up 4% year-on-year; the environmental sector increased from $892 million to $958 million, up 8% year-on-year, and the oral sector increased from $688 million to 7.15. The US dollar rose by 4% year-on-year, while the industrialization sector fell by 1% year-on-year, from $865 million to $859 million.
In addition, Danaher also announced that starting from Q3, the financial statements will cover only four business areas: Life Sciences (including Beckman Life Sciences), Diagnostics (including Beckman Diagnostics), and Dental and Environmental and Applied Solutions.
Roche Diagnostics: Half-year sales of 5.6 billion US dollars, an increase of 6%
Roche's total sales in the first half of this year reached 5.562 billion Swiss francs ($5.658 billion), an increase of 6% from the same period in 2015 of 5.24 billion Swiss francs. Among them, occupational diagnosis is the main growth point of its overall diagnosis business, accounting for nearly 60% of the business proportion, followed by diabetes care (17.94%), molecular diagnosis (16.24%), and tissue diagnosis (7.7%).
It is worth mentioning that compared with Roche, its diagnostic business is still small, accounting for only 22.2%. The growth of molecular diagnostics (sequencing and molecular business) is primarily driven by the Asia-Pacific region; while organizational diagnostic growth is primarily a contribution from North America. At present, most of the emerging diagnostic companies in China are in the field of molecular diagnosis and tissue diagnosis.
Abbott’s diagnosis: Q2 revenue was $5.33 billion, up 3% year-on-year
In February of this year, Abbott Diagnostics announced that it will spend $5.8 billion to acquire Alere and become a POCT overlord. Due to the twists and turns of the acquisition process, it is still under review.
Abbott announced in its earnings report that its Q2 revenue was 5.33 billion US dollars, up 3% from the 5.17 billion US dollars in the same period last year, higher than Wall Street's estimated 5.24 billion US dollars. Among them, the diagnostics department's sales were 1.23 billion US dollars, up 4% year-on-year; the central laboratory business grew 3% to 978 million US dollars; the molecular business grew nearly 5% to 119 million US dollars, and the instant diagnostic business grew 12% to 129 million US dollars. .
Wide Angle Ptz Camera,Wireless Camera Ip,Waterproof Wireless Cctv Camera,Outdoor Wifi Camera
Shenzhen Zuomi Technology Co., Ltd. , https://www.zuomicamera.com